

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☒ FADED TEXT OR DRAWING

☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.




FIG 1




FIG 2




FIG 3




FIG 4











FIG 5A




BRI6796




BRI6797



BRI6798




BRI6799




BRI6800


FIG 5B




BRI6801




BRI6802



BRIX114




BRI6803




BRI6814


FIG 5C




BRI6815




BRI6816



BRI6817




BRI6822




BRI6823


FIG 5D




BRI6824




BRI6825



BRI6829



BRI6855



BRI6856

FIG 5E






FIG 5F




BRI7009



BRI7012

FIG 5G


Inhibition or enhancement of FcγRIIIa binding to human IgG1.



Serial dilutions of compounds at specified concentrations, prefix BRI and designated as indicated, were preincubated with receptor and injected over IgG and extent of receptor binding determined (shown as Response Units - Y axis).

FIG 6


Inhibition or enhancement of FcγRIIIa binding to human IgG3.



Serial dilutions of compounds at specified concentrations, prefix BRI and designated as indicated, were preincubated with receptor and injected over IgG and extent of receptor binding determined (shown as Response Units - Y axis).

FIG 7


Inhibition or enhancement of FcγRIIIa binding to human IgG1.



Serial dilutions of compounds at specified concentrations, prefix BRI and designated as indicated, were preincubated with receptor and injected over IgG and extent of receptor binding determined (shown as Response Units - Y axis).

FIG 8

Inhibition or enhancement of FcγRIIIa binding to human IgG3.



Serial dilutions of compounds at specified concentrations, prefix BRI and designated as Indicated, were preincubated with receptor and injected over IgG and extent of receptor binding determined (shown as Response Units - Y axis).

FIG 9

Enhanced sFcγRII binding






FIG 10

Inhibition of sFcγRIIIa binding




mg/ml tripeptide
FIG 11



Activation of platelets in the presence of agonist only.
Platelets ($100 \times 10^6/\text{ml}$) were mixed in the presence of Fc γ RIIa agonist (HAGG, $200 \mu\text{g}/\text{ml}$) and PBS and the rate of platelet aggregation was measured as the gradient of the change to percent light transmission (x) over time (y).

FIG 12



agonist and compound BRI 6855

Activation of platelets in the presence of agonist and BRI compound 6855.
Platelets ($100 \times 10^9/\text{ml}$) were mixed in the presence of FcγRIIIa agonist (HAGG, $200 \mu\text{g}/\text{ml}$) and compound BRI 6855 ($5 \text{ mg}/\text{ml}$) and the rate of platelet aggregation was measured as the gradient of the change to percent light transmission (x) over time (y).

FIG 13

Effect of BRI compound 6728 on platelet aggregation with HAGG




FIG 14